A method for making a monomer includes reacting an alkanol-substituted phenol with epihalohydrin in the presence of a phase transfer catalyst at a temperature of 50° C. or lower to produce a first intermediate product. The method further includes removing excess epihalohydrin, and after removing excess epihalohydrin, contacting the first intermediate product with a base to produce a second intermediate product, and forming an oxirane-functional vinyl monomer from the second intermediate product. The monomer includes an oxirane group, an unsaturated vinyl bond, and optionally an aromatic spacer between the two functional groups.

The invention provides an epoxy compound A represented by the following formula (1): ##STR00001## in the formula (1), Ar's each independently represent a structure having an unsubstituted or substituted aromatic ring; R.sub.1 and R.sub.2 each independently represent a hydrogen atom or an alkyl group having 1 or 2 carbon atoms; R.sub.3 to R.sub.8 represent a hydroxy group, a glycidyl ether group and/or a 2-methylglycidyl ether group, and at least one of R.sub.3 to R.sub.8 is a glycidyl ether group or a 2-methylglycidyl ether group; R.sub.9 to R.sub.12 represent a hydroxy group or a methyl group; n is an integer of 11 to 16; and m, p.sub.1, p.sub.2, and q are average values of repetition, m is 0.5 to 10, p.sub.1 and p.sub.2 are each independently 0 to 5, and q is 0.5 to 5 (provided that each repeating unit present in the repeating units may be the same or different).

The present invention relates to a fluorine-containing ether compound represented by Formula (1),
R.sup.1—R.sup.2—CH.sub.2—R.sup.3—CH.sub.2—R.sup.4  (1).
(In Formula (1), R.sup.1 is an end group including an organic group having at least one double bond or triple bond, R.sup.2 is a divalent linking group bonded to R.sup.1 by etheric oxygen, R.sup.3 is a perfluoropolyether chain, R.sup.4 is an end group having two or three polar groups with each polar group being bonded to different carbon atoms, and the carbon atoms, to which the polar groups are bonded, being bonded to each other via a linking group including carbon atoms to which the polar groups are not bonded.)

The present invention relates to a fluorine-containing ether compound represented by Formula (1),
R.sup.1—R.sup.2—CH.sub.2—R.sup.3—CH.sub.2—R.sup.4  (1).
(In Formula (1), R.sup.1 is an end group including an organic group having at least one double bond or triple bond, R.sup.2 is a divalent linking group bonded to R.sup.1 by etheric oxygen, R.sup.3 is a perfluoropolyether chain, R.sup.4 is an end group having two or three polar groups with each polar group being bonded to different carbon atoms, and the carbon atoms, to which the polar groups are bonded, being bonded to each other via a linking group including carbon atoms to which the polar groups are not bonded.)

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R(I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention provides an epoxy compound A represented by the following formula (1):

##STR00001## in the formula (1), Ar's each independently represent a structure having an unsubstituted or substituted aromatic ring; R.sub.1 and R.sub.2 each independently represent a hydrogen atom or an alkyl group having 1 or 2 carbon atoms; R.sub.3 to R.sub.8 represent a hydroxy group, a glycidyl ether group and/or a 2-methylglycidyl ether group, and at least one of R.sub.3 to R.sub.8 is a glycidyl ether group or a 2-methylglycidyl ether group; R.sub.9 to R.sub.12 represent a hydroxy group or a methyl group; n is an integer of 11 to 16; and m, p.sub.1, p.sub.2, and q are average values of repetition, m is 0.5 to 10, p.sub.1 and p.sub.2 are each independently 0 to 5, and q is 0.5 to 5 (provided that each repeating unit present in the repeating units may be the same or different).

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.